<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784029</url>
  </required_header>
  <id_info>
    <org_study_id>12-09-345</org_study_id>
    <nct_id>NCT01784029</nct_id>
  </id_info>
  <brief_title>Treatment Study of Vitamin D Deficiency in Adolescents</brief_title>
  <official_title>Comparison of Two Standard High-dose Treatment Regimens for Vitamin D Deficiency in Minority Adolescents: Associations of Vitamin D Repletion With Changes in Markers of Musculoskeletal, Cardiometabolic, and Immune Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of two high dose vitamin D3 regimens (5,000 IU daily vs. 50,000 IU
      weekly) used clinically for the treatment of vitamin D deficiency versus a low dose of
      vitamin D3 used for supplementation (1,000 IU daily) in a clinical sample of predominantly
      Hispanic and black adolescents with vitamin D deficiency [25(OH)D level &lt;20 ng/ml] by
      assessing change in 25(OH)D levels before and after 8 weeks of treatment.

      To compare the effects of vitamin D repletion [25(OH)D level &gt;20 ng/mL] on selected
      musculoskeletal, cardiometabolic and immune markers in predominantly Hispanic and black
      adolescents with vitamin D deficiency [25(OH)D level &lt; 20 ng/mL].

      Hypothesis 1: Increase in vitamin D level will be associated with improvement in
      musculoskeletal, cardiometabolic, and immune markers including blood pressure, waist
      circumference, musculoskeletal symptoms, asthma severity and hand-grip strength.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D is an essential nutrient and pro-hormone that has garnered widespread attention
      over the past decade for both its known and theorized health benefits. Patients, clinicians
      and researchers have all been alerted to the increasing prevalence of vitamin D deficiency
      (defined as level of 25(OH)D &lt;20 ng/mL) and the significance of the extra-skeletal health
      effects of vitamin D. Aside from the skeletal impacts of Vitamin D, there has been recent
      evidence about potential health benefits of vitamin D related to the multiple extra-skeletal
      roles of this hormone. In fact, vitamin D receptors are found in many organs including brain,
      heart, skin, small intestine, gonads, prostate and breast as well in almost all nucleated
      cells including osteoblasts, activated T and B-lymphocytes, and B islet cells. Studies in
      children and adolescents as well as in adults show associations of vitamin D deficiency with
      cardiovascular risk factors, musculoskeletal health, asthma, and autoimmune diseases.

      While Vitamin D deficiency is quite prevalent, adolescents who are obese or who are darker
      skinned are consistently shown to have higher rates of vitamin D deficiency than lean and
      lighter skinned adolescents. Treatment of vitamin D deficiency and maintenance of sufficient
      levels in adolescents are largely under-studied leaving patients and clinicians without clear
      evidence-based guidelines to follow.

      The goal of this study is to compare the efficacy of different treatment regimens for vitamin
      D deficiency in our population of predominantly minority adolescents and to examine the
      effect of correction of vitamin D deficiency on selected extra-skeletal targets of vitamin D
      action including musculoskeletal, cardiometabolic, and immune function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 25(OH)D Serum Level After Treatment for Vitamin D Deficiency (Deficiency Defined as 25(OH)D &lt;20 ng/dL)</measure>
    <time_frame>Baseline to 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VItamin D3 1,000 IU
1 x day, 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weekly High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 50,000 IU
1x week, 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 5,000 IU
1x day, 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
    <arm_group_label>Daily High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Weekly High Dose</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 13-20

        Exclusion Criteria:

          -  currently receiving treatment for hypovitaminosis D

          -  hepatic or renal disease

          -  metabolic rickets

          -  inability to complete the questionnaire
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M Coupey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital at Montefiore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital at Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 31, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <results_first_submitted>August 17, 2018</results_first_submitted>
  <results_first_submitted_qc>September 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2018</results_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Susan Coupey</investigator_full_name>
    <investigator_title>Chief, Adolescent Medicine</investigator_title>
  </responsible_party>
  <keyword>adolescents</keyword>
  <keyword>minority</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited aged 13â€“20 years from the Adolescent Medicine and Pediatric Endocrinology practices at Children's Hospital at Montefiore.</recruitment_details>
      <pre_assignment_details>Of the 305 adolescents screened, only 203 met the inclusion criteria of being vitamin D deficient. Of the 203 adolescents identified with vitamin D deficiency, 20 were unable to be further contacted and randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose</title>
          <description>VItamin D3 1,000 IU
1 x day, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
        </group>
        <group group_id="P2">
          <title>Weekly High Dose</title>
          <description>Vitamin D3 50,000 IU
1x week, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
        </group>
        <group group_id="P3">
          <title>Daily High Dose</title>
          <description>Vitamin D3 5,000 IU
1x day, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose</title>
          <description>VItamin D3 1,000 IU
1 x day, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
        </group>
        <group group_id="B2">
          <title>Weekly High Dose</title>
          <description>Vitamin D3 50,000 IU
1x week, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
        </group>
        <group group_id="B3">
          <title>Daily High Dose</title>
          <description>Vitamin D3 5,000 IU
1x day, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="183"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.8" spread="2.1"/>
                    <measurement group_id="B2" value="16.5" spread="2.4"/>
                    <measurement group_id="B3" value="16.6" spread="2.1"/>
                    <measurement group_id="B4" value="16.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in 25(OH)D Serum Level After Treatment for Vitamin D Deficiency (Deficiency Defined as 25(OH)D &lt;20 ng/dL)</title>
        <time_frame>Baseline to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>VItamin D3 1,000 IU
1 x day, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
          </group>
          <group group_id="O2">
            <title>Weekly High Dose</title>
            <description>Vitamin D3 50,000 IU
1x week, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
          </group>
          <group group_id="O3">
            <title>Daily High Dose</title>
            <description>Vitamin D3 5,000 IU
1x day, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 25(OH)D Serum Level After Treatment for Vitamin D Deficiency (Deficiency Defined as 25(OH)D &lt;20 ng/dL)</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="6.5"/>
                    <measurement group_id="O2" value="24.9" spread="15.1"/>
                    <measurement group_id="O3" value="21" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of study (1 year)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose</title>
          <description>VItamin D3 1,000 IU
1 x day, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
        </group>
        <group group_id="E2">
          <title>Weekly High Dose</title>
          <description>Vitamin D3 50,000 IU
1x week, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
        </group>
        <group group_id="E3">
          <title>Daily High Dose</title>
          <description>Vitamin D3 5,000 IU
1x day, 8 weeks
Vitamin D3: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Substantial attrition rate is a limitation of this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Hina Talib</name_or_title>
      <organization>Children's Hospital at Montefiore</organization>
      <phone>718-920-6781</phone>
      <email>htalib@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

